BioWorld Science

April 16, 2019

View Archived Issues

Using promiscuity to identify high-commitment targets

Read More

Local vaccine can induce global remission

Read More

Design of EBNA1-specific inhibitors suppressing Epstein-Barr virus-driven tumor growth

Read More

CCR1 is differentially expressed across ovarian cancer subtypes

Read More

Phase II dose of cancer vaccine IMU-131 identified in HER2/neu-overexpressing stomach cancer trial

Read More

Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint

Read More

Alnylam initiates global phase III pediatric ILLUMINATE-B study

Read More

Clinical program update on ADVM-022 gene therapy

Read More

Synapse formation important for ketamine durability

Read More

Preclinical characterization of PF-06882961

Read More

S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease

Read More

RTI-1092663 improves metabolic syndrome in mice

Read More

Shenyang Pharmaceutical University patents neuraminidase inhibitors

Read More

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

Read More

FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease

Read More

Diamyd Medical presents 30-month results from phase IIa EDCR study

Read More

MediciNova moves forward with a phase III study of MN-166 in ALS

Read More

CStone Pharmaceuticals announces dosing of first patient in phase III GEMSTONE-303 study

Read More

Positive interim results presented from phase I study of CERC-301

Read More

Positive 12-month data presented from phase II study of Clascoterone

Read More

Interim results presented from phase II study of chikungunya virus vaccine candidate

Read More

Cortexyme launches phase II/III study of COR-388 in subjects with Alzheimer's disease

Read More